Lilly’s solanezumab fails to meet objective in phase 2/3 DIAN-TU Study

This article was originally published here

Based on the result of the primary endpoint, Lilly has dropped its plan to pursue regulatory submission for solanezumab in people having dominantly inherited Alzheimer’s disease (DIAD) or

The post Lilly’s solanezumab fails to meet objective in phase 2/3 DIAN-TU Study appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply